MediWound Statistics
Total Valuation
MediWound has a market cap or net worth of $201.13 million. The enterprise value is $178.50 million.
Important Dates
The next confirmed earnings date is Thursday, August 14, 2025, before market open.
| Earnings Date | Aug 14, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
MediWound has 10.81 million shares outstanding. The number of shares has increased by 16.23% in one year.
| Current Share Class | 10.81M |
| Shares Outstanding | 10.81M |
| Shares Change (YoY) | +16.23% |
| Shares Change (QoQ) | +0.34% |
| Owned by Insiders (%) | 1.75% |
| Owned by Institutions (%) | 40.17% |
| Float | 7.70M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.10 |
| Forward PS | 7.56 |
| PB Ratio | 6.47 |
| P/TBV Ratio | 10.12 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 8.99 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.48, with a Debt / Equity ratio of 0.40.
| Current Ratio | 1.48 |
| Quick Ratio | 1.35 |
| Debt / Equity | 0.40 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -148.65% and return on invested capital (ROIC) is -52.76%.
| Return on Equity (ROE) | -148.65% |
| Return on Assets (ROA) | -22.25% |
| Return on Invested Capital (ROIC) | -52.76% |
| Return on Capital Employed (ROCE) | -58.33% |
| Revenue Per Employee | $178,901 |
| Profits Per Employee | -$254,360 |
| Employee Count | 111 |
| Asset Turnover | 0.32 |
| Inventory Turnover | 4.59 |
Taxes
In the past 12 months, MediWound has paid $82,000 in taxes.
| Income Tax | 82,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +0.49% in the last 52 weeks. The beta is 0.22, so MediWound's price volatility has been lower than the market average.
| Beta (5Y) | 0.22 |
| 52-Week Price Change | +0.49% |
| 50-Day Moving Average | 19.78 |
| 200-Day Moving Average | 18.32 |
| Relative Strength Index (RSI) | 38.10 |
| Average Volume (20 Days) | 65,206 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, MediWound had revenue of $19.86 million and -$28.23 million in losses. Loss per share was -$2.63.
| Revenue | 19.86M |
| Gross Profit | 3.66M |
| Operating Income | -22.12M |
| Pretax Income | -12.55M |
| Net Income | -28.23M |
| EBITDA | -21.28M |
| EBIT | -22.12M |
| Loss Per Share | -$2.63 |
Full Income StatementBalance Sheet
The company has $32.44 million in cash and $8.07 million in debt, giving a net cash position of $24.37 million or $2.25 per share.
| Cash & Cash Equivalents | 32.44M |
| Total Debt | 8.07M |
| Net Cash | 24.37M |
| Net Cash Per Share | $2.25 |
| Equity (Book Value) | 20.12M |
| Book Value Per Share | 1.86 |
| Working Capital | 14.01M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$15.26 million and capital expenditures -$4.01 million, giving a free cash flow of -$19.27 million.
| Operating Cash Flow | -15.26M |
| Capital Expenditures | -4.01M |
| Free Cash Flow | -19.27M |
| FCF Per Share | -$1.78 |
Full Cash Flow StatementMargins
Gross margin is 18.43%, with operating and profit margins of -111.41% and -142.18%.
| Gross Margin | 18.43% |
| Operating Margin | -111.41% |
| Pretax Margin | -141.77% |
| Profit Margin | -142.18% |
| EBITDA Margin | -107.15% |
| EBIT Margin | -111.41% |
| FCF Margin | n/a |
Dividends & Yields
MediWound does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -16.23% |
| Shareholder Yield | -16.23% |
| Earnings Yield | -13.92% |
| FCF Yield | -9.50% |
Analyst Forecast
The average price target for MediWound is $35.00, which is 88.07% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.00 |
| Price Target Difference | 88.07% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | 41.78% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on December 20, 2022. It was a reverse split with a ratio of 1:7.
| Last Split Date | Dec 20, 2022 |
| Split Type | Reverse |
| Split Ratio | 1:7 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |
